STAT+: FDA staff reiterate concerns about Replimune skin cancer treatment

MAP Verified Summary — reported by STAT News

Regulators at the FDA have reiterated concerns that Replimmune does not have adequate data to support an approval of its investigational skin cancer treatment.

This story was scored across MAP’s five-signal verification framework — Context, Presentation, References, Visibility, and Comparison — as part of Media Alert Press’s independent media credibility index. Read the full original story at STAT News →